Palliative chemotherapy after failure of high-dose chemotherapy in breast cancer - Toxicity and efficacy

被引:0
作者
Schrama, JG [1 ]
De Boer, MMD [1 ]
Baars, JW [1 ]
Schornagel, JH [1 ]
Rodenhuis, S [1 ]
机构
[1] Netherlands Canc Inst, Dept Med Oncol, NL-1066 CX Amsterdam, Netherlands
关键词
high-dose chemotherapy; peripheral blood progenitor cell transplantation; metastatic breast cancer; primary breast cancer; palliative chemotherapy;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We evaluated the toxicity and efficacy of the first palliative chemotherapy regimen after failure of high-dose chemotherapy in 148 patients with primary or metastatic breast cancer treated with high-dose chemotherapy (one full dose CTC (cyclophosphamide 6000 mg/m(2), thiotepa 480 mg/m(2), carboplatin 1600 mg/m(2)) or multiple courses CTC or 'tiny' CTC (tCTC) (two-thirds of the agents of the full-dose regimen), all divided over 4 days). After a median follow-up time of 46.8 (range 1-120) months, 79 patients had a relapse or progressive disease and 41 patients were treated with palliative chemotherapy. The most commonly used regimens were classical CMF (n=13), docetaxel (n=16) and less frequently anthracycline (n=4), paclitaxel (n=5), capecitabine (n=2) and vinorelbine (n=2). In both the CMF and docetaxel group, 3 patients required a dose reduction because of hematological toxicity. Objective responses were seen with CMF (23%) and docetaxel (69%) with a median duration of 161 (range 28481) and 196 (range 62-437) days, respectively. We found no relationship of toxicity and response with treatment free interval after high-dose chemotherapy. This report shows that conventional-dose palliative chemotherapy regimens may be safe and effective after failure of high-dose chemotherapy.
引用
收藏
页码:2795 / 2800
页数:6
相关论文
共 21 条
  • [1] Responses to docetaxel plus virorelbine in metastatic breast cancer patients failing high-dose chemotherapy
    Andres, R
    Mayordomo, JI
    Isla, D
    Marti, JL
    Escudero, P
    Filipovich, E
    Saenz, A
    Alvarez, I
    Polo, E
    Tres, A
    [J]. BRITISH JOURNAL OF CANCER, 2002, 86 (06) : 1017 - 1018
  • [2] High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America
    Antman, KH
    Rowlings, PA
    Vaughan, WP
    Pelz, CJ
    Fay, JW
    Fields, KK
    Freytes, CO
    Gale, RP
    Hillner, BE
    Holland, HK
    Kennedy, MJ
    Klein, JP
    Lazarus, HM
    McCarthy, PL
    Saez, R
    Spitzer, G
    Stadtmauer, EA
    Williams, SF
    Wolff, S
    Sobocinski, KA
    Armitage, JO
    Horowitz, MM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (05) : 1870 - 1879
  • [3] Bashey A, 2001, CLIN ONCOL-UK, V13, P434
  • [4] Reinfusion of autologous lymphocytes with granulocyte-macrophage colony-stimulating factor induces rapid recovery of CD4+ and CD8+ T cells after high-dose chemotherapy for metastatic breast cancer
    de Gast, GC
    Vyth-Dreese, FA
    Nooijen, W
    van den Bogaard, CJC
    Sein, J
    Holtkamp, MMJ
    Linthorst, GAM
    Baars, JW
    Schornagel, JH
    Rodenhuis, S
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) : 58 - 64
  • [5] Esteva FJ, 2002, ONCOLOGY-NY, V16, P17
  • [6] Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma
    Hortobagyi, GN
    Buzdar, AU
    Theriault, RL
    Valero, V
    Frye, D
    Booser, DJ
    Holmes, FA
    Giralt, S
    Khouri, I
    Andersson, B
    Gajewski, JL
    Rondon, G
    Smith, TL
    Singletary, SE
    Ames, FC
    Sneige, N
    Strom, EA
    McNeese, MD
    Deisseroth, AB
    Champlin, RE
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (03): : 225 - 233
  • [7] Capecitabine in patients with breast cancer relapsing after high-dose chemotherapy plus autologous peripheral stem cell transplantation - a phase II study
    Jakob, A
    Bokemeyer, C
    Knop, S
    Schupp, M
    Mayer, F
    Kanz, L
    [J]. ANTI-CANCER DRUGS, 2002, 13 (04) : 405 - 410
  • [8] Docetaxel in the treatment of breast cancer: An update on recent studies
    Nabholtz, JMA
    Reese, DM
    Lindsay, MA
    Riva, A
    [J]. SEMINARS IN ONCOLOGY, 2002, 29 (03) : 28 - 34
  • [9] *NAT CANC I, 1998, GUID REP ADV DRUG RE
  • [10] Evaluation of the predictive value of Her-2/neu overexpression and p53 mutations in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplantation
    Nieto, Y
    Cagnoni, PJ
    Nawaz, S
    Shpall, EJ
    Yerushalmi, R
    Cook, B
    Russell, P
    McDermit, J
    Murphy, J
    Bearman, SI
    Jones, RB
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (10) : 2070 - 2080